Evidence map›Paper›PMID 33930640›Full record

ArticleDrug and alcohol dependence2021

Developing a cognitive dysfunction risk score for use with opioid-dependent persons in drug treatment.

Michael M Copenhaver, Victoria Sanborn, Roman Shrestha, Colleen B Mistler, Matthew C Sullivan, John Gunstad

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol dependence, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael M CopenhaverDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA; Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT, USA.
Victoria SanbornDepartment of Psychological Sciences and Brain Health Research Institute, Kent State University, Kent, OH, USA.
Roman ShresthaDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA; Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT, USA. Electronic address: roman.shrestha@uconn.edu.
Colleen B MistlerDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA; Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT, USA.
Matthew C SullivanDepartment of Allied Health Sciences, University of Connecticut, Storrs, CT, USA; Institute for Collaboration on Health, Intervention, and Policy, University of Connecticut, Storrs, CT, USA.
John GunstadDepartment of Psychological Sciences and Brain Health Research Institute, Kent State University, Kent, OH, USA.

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Training in Social Processes of HIV/AIDST32MH074387 · NIMH · UNIVERSITY OF CONNECTICUT STORRS · PI KALICHMAN, SETH C · 2006 to 2020
$3.9M
Testing an integrated bio-behavioral primary HIV prevention intervention among high-risk people who use drugsR01DA044867 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI COPENHAVER, MICHAEL · 2017 to 2021
$3.2M
Secondary HIV Prevention and Adherence Among HIV-infected Drug UsersR01DA032290 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI COPENHAVER, MICHAEL · 2012 to 2016
$3.1M
Spontaneous Speech and Health Disparities in Risk of Cognitive Decline: WHICAP Offspring Ancillary StudyR01AG065432 · NIA · KENT STATE UNIVERSITY · PI BRICKMAN, ADAM M, GUNSTAD, JOHN J. · 2020 to 2023
$2.6M
Optimizing HIV Prevention Among Opioid-Dependent PersonsK24DA051344 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI MICHAEL COPENHAVER · 2020 to 2026
$1.3M
Training in MHealth Prevention with MSMK01DA051346 · NIDA · YALE UNIVERSITY · PI SHRESTHA, ROMAN · 2020 to 2024
$862k
Integrated Rapid Access to HIV Prevention Program for People Who Inject Drugs (RAPID)R21DA051934 · NIDA · YALE UNIVERSITY · PI SHRESTHA, ROMAN · 2020 to 2021
$457k
NCATS NIH HHS UL1 TR001863NIA NIH HHS R01 AG065432NIDA NIH HHS K01 DA051346NIDA NIH HHS K24 DA051344NIDA NIH HHS R01 DA032290NIDA NIH HHS R01 DA044867NIDA NIH HHS R21 DA051934NIMH NIH HHS T32 MH074387
6 · The paper itself

Abstract

backgroundCognitive dysfunction is common in persons seeking medication for opioid use disorder (MOUD) and may hinder many addiction-related services. Brief but accurate screening measures are needed to efficiently assess cognitive dysfunction in these resource-limited settings. The study aimed to develop a brief predictive risk score tailored for use among patients in drug treatment.

methodsThe present study examined predictors of mild cognitive impairment (MCI), objectively assessed via the NIH Toolbox, among 173 patients receiving methadone as MOUD at an urban New England drug treatment facility. Predictors of MCI were identified in one subsample using demographic characteristics, medical chart data, and selected items from the Brief Inventory of Neuro-Cognitive Impairment (BINI). Predictors were cross-validated in a second subsample using logistic regression. Receiver operating curve (ROC) analyses determined an optimal cut-off score for detecting MCI.

resultsA cognitive dysfunction risk score (CDRS) was calculated from patient demographics (age 50+, non-White ethnicity, less than high school education), medical and substance use chart data (history of head injury, overdose, psychiatric diagnosis, past year polysubstance use), and selected self-report items (BINI). The CDRS discriminated acceptably well, with a ROC curve area of 70.6 %, and correctly identified 78 % of MCI cases (sensitivity = 87.5 %; specificity = 55.6 %).

conclusionsThe CDRS identified patients with cognitive challenges at a level likely to impede treatment engagement and/or key outcomes. The CDRS may assist in efficiently identifying patients with cognitive dysfunction while requiring minimal training and resources. Larger validation studies are needed in other clinical settings.

Indexed as

Cognitive DysfunctionPharmaceutical PreparationsAnalgesics, OpioidHumansMass ScreeningMiddle AgedNeuropsychological TestsRisk FactorsROC CurveSensitivity and SpecificityAnalgesics, OpioidPharmaceutical PreparationsBrief inventory for neurocognitive impairmentCognitive dysfunctionMedication for opioid use disorderOpioid-dependentRisk score

Identifiers

PMID33930640
PMCPMC8180490

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.